On April 17, 2026, Corvus Pharmaceuticals Inc CRVS experienced a notable increase in its stock price following a Buy rating initiated by Goldman Sachs, which set a price target of $40. Analyst Paul Choi highlighted the potential of the company's lead candidate, soquelitinib, which is being developed for atopic dermatitis and other autoimmune disorders. With shares up over 400% in the past year, Choi emphasized that the stock is currently undervalued, considering forthcoming catalysts over the next 12-18 months.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.